Literature DB >> 26375306

Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding.

Yvonne V Sanders1, Karin Fijnvandraat2, Johan Boender1, Evelien P Mauser-Bunschoten3, Johanna G van der Bom4,5, Joke de Meris6, Frans J Smiers7, Bernd Granzen8, Paul Brons9, Rienk Y J Tamminga10, Marjon H Cnossen11, Frank W G Leebeek1.   

Abstract

The bleeding phenotype of children with von Willebrand disease (VWD) needs to be characterized in detail to facilitate diagnosis during childhood and aid in the planning and assessment of treatment strategies. The objective was to evaluate the occurrence, type, and severity of bleeding in a large cohort of children with moderate and severe VWD. We included 113 children (aged 0-16 years) with Type 1 (n = 60), 2 (n = 44), and 3 (n = 9) VWD with von Willebrand factor (VWF) antigen and/or VWF ristocetin cofactor levels ≤ 30 U/dL from a nation-wide cross-sectional study ("Willebrand in the Netherlands" study). Bleeding severity and frequency were determined using the International Society on Thrombosis and Hemostasis-Bleeding Assessment Tool (ISTH-BAT) with supplementary pediatric-specific bleeding symptoms (umbilical stump bleeding, cephalohematoma, cheek hematoma, conjunctival bleeding, postcircumcision and postvenipuncture bleeding). We found that all 26 postmenarche girls experienced menorrhagia. Other common bleedings were cutaneous (81%), oropharyngeal (64%), prolonged bleeding from minor wounds (58%), and epistaxis (56%). Pediatric-specific bleeding symptoms were present in 44% of patients. ISTH-BAT bleeding score was higher in index cases than in affected family members (median, 12.0 vs. 6.5, P < 0.001), higher in Type 3 VWD than in Type 2 or 1 (17.0 vs. 10.5 or 6.5, P < 0.001) and higher in children with severe (<10 U/dL) than moderate VWD (10-30 U/dL) (11.0 vs. 7.0, P < 0.001). Frequency of any bleeding, epistaxis, and oral cavity was higher in types 2 and 3 than in Type 1 VWD and was associated with VWF levels. We conclude that pediatric-specific bleeding symptoms occurred in a large proportion of children with moderate or severe VWD and should be included when evaluating children for VWD.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26375306     DOI: 10.1002/ajh.24195

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

Review 1.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

2. 

Authors:  Tyler Yan; Ran D Goldman
Journal:  Can Fam Physician       Date:  2021-06       Impact factor: 3.275

3.  New advances in the diagnosis of von Willebrand disease.

Authors:  Ruchika Sharma; Sandra L Haberichter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 4.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy.

Authors:  Ozlem Turan; Rezan Abdul Kadir
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 6.  Von Willebrand Disease: Current Status of Diagnosis and Management.

Authors:  Angela C Weyand; Veronica H Flood
Journal:  Hematol Oncol Clin North Am       Date:  2021-08-13       Impact factor: 3.722

7.  Recurrent epistaxis in children.

Authors:  Tyler Yan; Ran D Goldman
Journal:  Can Fam Physician       Date:  2021-06       Impact factor: 3.275

Review 8.  New developments in von Willebrand disease.

Authors:  Helen Fogarty; Dearbhla Doherty; James S O'Donnell
Journal:  Br J Haematol       Date:  2020-05-12       Impact factor: 6.998

9.  Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease.

Authors:  Karon Abe; Brandi Dupervil; Sarah H O'Brien; Meredith Oakley; Roshni Kulkarni; Joan Cox Gill; Vanessa Byams; Michael J Soucie
Journal:  Am J Hematol       Date:  2019-10-29       Impact factor: 13.265

Review 10.  Von Willebrand disease in the elderly: clinical perspectives.

Authors:  John Chapin
Journal:  Clin Interv Aging       Date:  2018-08-31       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.